Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 1, 2008, Pages

  Vinet, Laurent ^a,d   Rouet Benzineb, Patricia ^a   Marniquet, Xavier ^a   Pellegrin, Noémie ^a   Mangin, Laurence ^a,c   Louedec, Liliane ^a   Samuel, Jane Lise ^a   Mercadier, Jean Jacques ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Hopitaux de Paris   (France)

^d INSERM   (France)

Author keywords

Echocardiography; Heart catheterization; Matrix metalloproteinase; Pressure overload

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOXYCYCLINE; GELATINASE A; GELATINASE B; MYOSIN HEAVY CHAIN BETA; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; UNCLASSIFIED DRUG; ATP2A2 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; MYOSIN HEAVY CHAIN; PHOSPHOLAMBAN; PROTEINASE INHIBITOR; RYANODINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; GENE EXPRESSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; TRANSGENE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ECHOGRAPHY; ENZYMOLOGY; FIBROSIS; GENETICS; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; LIGATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ANIMALS; AORTA, THORACIC; CALCIUM-BINDING PROTEINS; CONSTRICTION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOXYCYCLINE; FIBROSIS; HEART FAILURE; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MYOCARDIUM; MYOSIN HEAVY CHAINS; NATRIURETIC PEPTIDE, BRAIN; POLYMERASE CHAIN REACTION; PROTEASE INHIBITORS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TIME FACTORS; VENTRICULAR REMODELING;

EID: 49849086014     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01101.2007     Document Type: Article

References (40)

1. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 93: 14014-14019, 1996.
2. Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett 410: 259-264, 1997.
3. Barrick CJ, Rojas M, Schoonhoven R, Smyth SS, Threadgill DW. Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 292: H2119-H2130, 2007.
4. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100: 2189-2195, 1997.
5. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89: 201-210, 2001.
6. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, Sicard GA, Thompson RW. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 31: 325-342, 2000.
7. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21: 1939-1947, 2002.
8. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91: 9302-9306, 1994.
9. Gellen B, Fernandez-Velasco M, Briec F, Vinet L, LeQuang K, Rouet-Benzineb P, Benitah JP, Pezet M, Palais G, Pellegrin N, Zhang A, Perrier R, Escoubet B, Marniquet X, Richard S, Jaisser F, Gomez AM, Charpentier F, Mercadier JJ. Conditional FKBP12.6 overexpression in mouse cardiac myocytes prevents triggered ventricular tachycardia through specific alterations in excitation-contraction coupling. Circulation 117: 1778-1786, 2008.
10. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12: 12-26, 1998.
11. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769, 1995.
12. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166: 15-25, 2005.
13. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285: H1261-H1269, 2003.
14. Hwang DY, Chae KR, Shin DH, Hwang JH, Lim CH, Kim YJ, Kim BJ, Goo JS, Shin YY, Jang IS, Cho JS, Kim YK. Xenobiotic response in humanized double transgenic mice expressing tetracycline-controlled transactivator and human CYP1B1. Arch Biochem Biophys 395: 32-40, 2001.
15. Kiriazis H, Sato Y, Kadambi VJ, Schmidt AG, Gerst MJ, Hoit BD, Kranias EG. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc Res 53: 372-381, 2002.
16. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47: 711-717, 2006.
17. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, De Windt LJ, Ludosky MA, Paulin D, Daegelen D, Tuil D, Li Z. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112: 2930-2939, 2005.
18. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103: 2303-2309, 2001.
19. Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 8: 602-610, 1995.
20. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 44: 1609-1618, 2004.
21. 2 by minocycline and doxycycline. Biochem Pharmacol 44: 1165-1170, 1992.
22. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, Conklin BR. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol 17: 165-169, 1999.
23. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci USA 97: 4826 - 4831, 2000.
24. Rothermel BA, Berenji K, Tannous P, Kutschke W, Dey A, Nolan B, Yoo KD, Demetroulis E, Gimbel M, Cabuay B, Karimi M, Hill JA. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure. Physiol Genomics 23: 18-27, 2005.
25. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, Harf A, Lafuma C. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1: 337-352, 1999.
26. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92: 609-616, 2003.
27. Schultz Jel J, Glascock BJ, Witt SA, Nieman ML, Nattamai KJ, Liu LH, Lorenz JN, Shull GE, Kimball TR, Periasamy M. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol 286: H1146-H1153, 2004.
28. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
29. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46: 225-238, 2000.
30. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP, Squires CG, Stroud RE, Ikonomidis JS. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther 318: 966-973, 2006.
31. Suarez J, Gloss B, Belke DD, Hu Y, Scott B, Dieterle T, Kim YK, Valencik ML, McDonald JA, Dillmann WH. Doxycycline inducible expression of SERCA2a improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 287: H2164-H2172, 2004.
32. Suzuki J, Shen WJ, Nelson BD, Patel S, Veerkamp JH, Selwood SP, Murphy GM Jr, Reaven E, Kraemer FB. Absence of cardiac lipid accumulation in transgenic mice with heart-specific HSL overexpression. Am J Physiol Endocrinol Metab 281: E857-E866, 2001.
33. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115: 1221-1231, 2005.
34. Tessone A, Feinberg MS, Barbash IM, Reich R, Holbova R, Richmann M, Mardor Y, Leor J. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 19: 383-390, 2005.
35. Valencik ML, McDonald JA. Codon optimization markedly improves doxycycline regulated gene expression in the mouse heart. Transgenic Res 10: 269-275, 2001.
36. Vieillard-Baron A, Frisdal E, Eddahibi S, Deprez I, Baker AH, Newby AC, Berger P, Levame M, Raffestin B, Adnot S, d'Ortho MP. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 87: 418-425, 2000.
37. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108: 1487-1492, 2003.
38. Wang QD, Bohlooly YM, Sjoquist PO. Murine models for the study of congestive heart failure: Implications for understanding molecular mechanisms and for drug discovery. J Pharmacol Toxicol Methods 50: 163-174, 2004.
39. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109: 255-261, 2004.
40. Yu Z, Redfern CS, Fishman GI. Conditional transgene expression in the heart. Circ Res 79: 691-697, 1996.